SG11201503728XA - N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors - Google Patents

N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Info

Publication number
SG11201503728XA
SG11201503728XA SG11201503728XA SG11201503728XA SG11201503728XA SG 11201503728X A SG11201503728X A SG 11201503728XA SG 11201503728X A SG11201503728X A SG 11201503728XA SG 11201503728X A SG11201503728X A SG 11201503728XA SG 11201503728X A SG11201503728X A SG 11201503728XA
Authority
SG
Singapore
Prior art keywords
thiourea
pyrrolidinyl
guanidine
pyrazolyl
urea
Prior art date
Application number
SG11201503728XA
Inventor
Shelley Allen
Barbara J Brandhuber
Timothy Kercher
Gabrielle R Kolakowski
Shannon L Winski
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of SG11201503728XA publication Critical patent/SG11201503728XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
SG11201503728XA 2012-11-13 2013-11-12 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors SG11201503728XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725913P 2012-11-13 2012-11-13
PCT/US2013/069729 WO2014078323A1 (en) 2012-11-13 2013-11-12 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201503728XA true SG11201503728XA (en) 2015-06-29

Family

ID=49667600

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503728XA SG11201503728XA (en) 2012-11-13 2013-11-12 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Country Status (32)

Country Link
US (2) US9896435B2 (en)
EP (2) EP3409670B1 (en)
JP (3) JP6316834B2 (en)
KR (1) KR102181915B1 (en)
CN (2) CN107857755B (en)
AU (2) AU2013344943B2 (en)
BR (1) BR112015010875B1 (en)
CA (1) CA2890876C (en)
CL (1) CL2015001261A1 (en)
CY (1) CY1120099T1 (en)
DK (1) DK2922844T3 (en)
ES (2) ES2834027T3 (en)
HK (1) HK1215438A1 (en)
HR (1) HRP20180331T1 (en)
HU (1) HUE038512T2 (en)
IL (1) IL238496B (en)
LT (1) LT2922844T (en)
ME (1) ME02990B (en)
MX (2) MX365733B (en)
MY (1) MY178262A (en)
NO (1) NO2876058T3 (en)
NZ (1) NZ708028A (en)
PH (1) PH12015500939B1 (en)
PL (1) PL2922844T3 (en)
PT (1) PT2922844T (en)
RS (1) RS57001B1 (en)
RU (1) RU2677667C2 (en)
SG (1) SG11201503728XA (en)
SI (1) SI2922844T1 (en)
UA (1) UA116455C2 (en)
WO (1) WO2014078323A1 (en)
ZA (1) ZA201503587B (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
UY32192A (en) 2008-10-22 2011-05-31 Array Biopharma Inc PIRAZOLO COMPOUNDS [1,5-a] PIRIMIDINE REPLACED AS TRK CINASA INHIBITORS
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
LT2712358T (en) 2011-05-13 2017-01-25 Array Biopharma, Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
NZ708028A (en) 2012-11-13 2018-12-21 Array Biopharma Inc N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
DK2920166T3 (en) 2012-11-13 2017-02-06 Array Biopharma Inc SUITABLE BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDE COMPOUNDS FOR PAIN TREATMENT
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CN105814019B (en) 2013-11-28 2019-12-06 杏林制药株式会社 Urea derivative or pharmacologically acceptable salt thereof
ES2746530T3 (en) * 2014-05-15 2020-03-06 Array Biopharma Inc 1 - ((3S, 4R) -4- (3-fluorophenyl) -1- (2-methoxyethyl) pyrrolidin-3-yl) -3- (4-methyl-3- (2-methylpyrimidin-5-yl) - 1-phenyl-1H-pyrazol-5-yl) urea as a TrkA kinase inhibitor
US10160727B2 (en) 2014-08-06 2018-12-25 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TrkA inhibitory activity
KR102649887B1 (en) 2014-11-16 2024-03-22 어레이 바이오파마 인크. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
EA201792679A1 (en) 2015-06-01 2018-06-29 Локсо Онколоджи, Инк. METHODS OF DIAGNOSTICS AND TREATMENT OF MALIGNANT TUMOR
EP3330256B1 (en) 2015-07-07 2021-06-16 Shionogi & Co., Ltd. HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY
TN2018000027A1 (en) 2015-07-16 2019-07-08 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
EP3412663B1 (en) 2016-02-04 2022-09-07 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having trka inhibitory activity
MX2018012163A (en) 2016-04-04 2019-07-08 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrro lidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide.
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3439663A1 (en) 2016-04-04 2019-02-13 Loxo Oncology Inc. Methods of treating pediatric cancers
JP7443057B2 (en) 2016-05-18 2024-03-05 ロクソ オンコロジー, インコーポレイテッド (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine -1-Preparation of carboxamide
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
JP2019026646A (en) * 2017-08-03 2019-02-21 塩野義製薬株式会社 Pharmaceutical composition for treating or preventing pain, containing nitrogen-containing heterocyclic and carbocyclic derivative
JP6986565B2 (en) 2017-09-29 2021-12-22 田辺三菱製薬株式会社 Optically active pyrrolidine compound and its production method
TWI812649B (en) 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
MA50456A (en) 2017-10-26 2020-09-02 Array Biopharma Inc MACROCYCLIC KINASE TRK INHIBITOR FORMULATIONS
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3762380B1 (en) 2018-03-05 2021-12-15 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
EP3822266A4 (en) * 2018-07-12 2022-04-27 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd Pyrrolidinyl urea derivatives and application thereof in trka-related diseases
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN110964016B (en) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 Amino-norbornane derivative and preparation method and application thereof
JP2022515197A (en) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド 7-((3,5-dimethoxyphenyl) amino) quinoxaline derivative as an FGFR inhibitor for treating cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN112979615A (en) * 2019-12-17 2021-06-18 上海医药集团股份有限公司 Quinazoline urea compound, preparation method, preparation intermediate, pharmaceutical composition and application thereof
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN117836289A (en) * 2021-04-12 2024-04-05 上海睿跃生物科技有限公司 Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use thereof
CN113278409B (en) * 2021-06-22 2022-04-29 西南石油大学 High-temperature acidizing corrosion inhibitor
CN114031556B (en) * 2021-11-08 2023-03-31 温州大学 Synthetic method for preparing 5-amino-N-aryl-3-arylpyrazole compound by green one-pot method
WO2024061768A1 (en) 2022-09-19 2024-03-28 Basf Se Azole pesticidal compounds

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679887B2 (en) 1995-09-11 1997-07-10 Nihon Nohyaku Co., Ltd. Azole derivatives, their use, production and usage
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
JP2001521934A (en) 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Aromatic heterocyclic compounds as anti-inflammatory drugs
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
DE69836563T2 (en) 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBITION OF p38 KINASE ACTIVITY THROUGH THE USE OF ARYL AND HETEROARYL SUBSTITUTED UREAS
ATE529109T1 (en) 1997-12-22 2011-11-15 Bayer Healthcare Llc INHIBITION OF P38 KINASE ACTIVITY BY SUBSTITUTED HETEROCYCLIC UREAS
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
KR100711538B1 (en) 1998-12-25 2007-04-27 아스카 세이야쿠 가부시키가이샤 Aminopyrazole derivatives
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6410533B1 (en) 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
AU2001273129A1 (en) 2000-06-30 2002-01-14 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
US20050009815A1 (en) 2001-11-27 2005-01-13 Devita Robert J. 4-Aminoquinoline compounds
SE0104248D0 (en) 2001-12-14 2001-12-14 Astrazeneca Ab Method of treatment
CA2490470A1 (en) 2002-07-02 2004-01-15 Schering Corporation Pyrazole urea neuropeptide y y5 receptor antagonists
DK1556083T3 (en) 2002-10-08 2011-04-04 Rinat Neuroscience Corp Method of treating post-operative pain by administration of an antibody to nerve growth factor and composition containing the same
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
WO2005024755A2 (en) 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
KR101150324B1 (en) 2003-06-12 2012-06-13 아보트 러보러터리즈 Fused compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
US7767670B2 (en) 2003-11-13 2010-08-03 Ambit Biosciences Corporation Substituted 3-carboxamido isoxazoles as kinase modulators
US20080220497A1 (en) 2003-12-24 2008-09-11 Flynn Daniel L Modulation of protein functionalities
JP4573223B2 (en) 2004-01-23 2010-11-04 東レ・ファインケミカル株式会社 Process for producing optically active trans-4-amino-1-benzyl-3-pyrrolidinol
CN101010315A (en) 2004-04-30 2007-08-01 拜耳制药公司 Substituted pyrazolyl urea derivatives useful in the treatment of cancer
JP2008524213A (en) 2004-12-20 2008-07-10 アストラゼネカ・アクチエボラーグ Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
CA2592116A1 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
JP2008526723A (en) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Pyrazole derivatives that modulate the activity of CDK, GSK and Aurora kinase
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
EP1960394A2 (en) 2005-11-15 2008-08-27 Bayer HealthCare AG Pyrazolyl urea derivatives useful in the treatment of cancer
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20110195110A1 (en) 2005-12-01 2011-08-11 Roger Smith Urea compounds useful in the treatment of cancer
WO2008016811A2 (en) 2006-07-31 2008-02-07 Neurogen Corporation Aminopiperidines and realted compounds
EP2049542B1 (en) 2006-08-09 2012-09-19 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20080261961A1 (en) 2007-04-20 2008-10-23 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
ITMI20071731A1 (en) 2007-09-06 2009-03-07 Univ Degli Studi Genova NEW UREIC DERIVATIVES OF 1H-PIRAZOL-4-CARBOXYLIC ACID WITH INHIBITIVE ACTIVITY TOWARDS NEUTRROPHILES CHEMOTASSASSES
EP2300469B1 (en) * 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
USRE49686E1 (en) * 2008-09-19 2023-10-10 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MX2011003312A (en) 2008-10-09 2011-04-26 Hoffmann La Roche Pyrrolidine n-benzyl derivatives.
UY32192A (en) 2008-10-22 2011-05-31 Array Biopharma Inc PIRAZOLO COMPOUNDS [1,5-a] PIRIMIDINE REPLACED AS TRK CINASA INHIBITORS
WO2010059719A2 (en) 2008-11-19 2010-05-27 Merial Limited Dimeric 1-arylpyrazole derivatives
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
CN102264737A (en) 2008-12-23 2011-11-30 雅培制药有限公司 Anti-viral compounds
CA2753061C (en) 2009-02-19 2016-08-09 Alexandros Makriyannis Novel hetero pyrrole analogs acting on cannabinoid receptors
US20120071475A1 (en) 2009-04-27 2012-03-22 Shionogi & Co., Ltd. Urea derivatives having pi3k-inhibiting activity
AR077468A1 (en) * 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
WO2011032291A1 (en) 2009-09-18 2011-03-24 Zalicus Pharmaceuticals Ltd . Selective calcium channel modulators
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
WO2012129258A1 (en) * 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
LT2712358T (en) * 2011-05-13 2017-01-25 Array Biopharma, Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
WO2014052566A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
NZ708028A (en) 2012-11-13 2018-12-21 Array Biopharma Inc N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
DK2920166T3 (en) 2012-11-13 2017-02-06 Array Biopharma Inc SUITABLE BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDE COMPOUNDS FOR PAIN TREATMENT
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
BR112015010875A2 (en) 2017-07-11
CL2015001261A1 (en) 2015-09-25
US20180179182A1 (en) 2018-06-28
ES2664331T3 (en) 2018-04-19
WO2014078323A1 (en) 2014-05-22
IL238496B (en) 2018-02-28
HUE038512T2 (en) 2018-10-29
CN107857755A (en) 2018-03-30
PT2922844T (en) 2018-04-02
JP2018048176A (en) 2018-03-29
AU2013344943B2 (en) 2017-06-29
JP2019081786A (en) 2019-05-30
NZ708028A (en) 2018-12-21
CA2890876A1 (en) 2014-05-22
RU2015122414A (en) 2017-01-10
MX2015006046A (en) 2015-12-01
KR102181915B1 (en) 2020-11-23
LT2922844T (en) 2018-03-26
UA116455C2 (en) 2018-03-26
EP3409670B1 (en) 2020-09-09
HK1215438A1 (en) 2016-08-26
KR20150084047A (en) 2015-07-21
RU2677667C2 (en) 2019-01-18
US20160280682A1 (en) 2016-09-29
BR112015010875A8 (en) 2019-10-01
JP2016501191A (en) 2016-01-18
PH12015500939A1 (en) 2015-06-29
CY1120099T1 (en) 2018-12-12
MX2019006834A (en) 2019-09-06
EP2922844B1 (en) 2018-01-10
IL238496A0 (en) 2015-06-30
CN104781255B (en) 2017-10-24
AU2017206195A1 (en) 2017-08-03
CN104781255A (en) 2015-07-15
US9896435B2 (en) 2018-02-20
CN107857755B (en) 2020-10-27
CA2890876C (en) 2021-01-19
MX365733B (en) 2019-06-12
RS57001B1 (en) 2018-05-31
AU2013344943A1 (en) 2015-06-04
ES2834027T3 (en) 2021-06-16
ME02990B (en) 2018-10-20
DK2922844T3 (en) 2018-03-05
EP2922844A1 (en) 2015-09-30
JP6316834B2 (en) 2018-04-25
HRP20180331T1 (en) 2018-05-04
SI2922844T1 (en) 2018-04-30
AU2017206195B2 (en) 2019-01-03
US10851080B2 (en) 2020-12-01
JP6482629B2 (en) 2019-03-13
ZA201503587B (en) 2020-11-25
EP3409670A1 (en) 2018-12-05
PH12015500939B1 (en) 2015-06-29
BR112015010875B1 (en) 2022-05-03
MY178262A (en) 2020-10-07
NO2876058T3 (en) 2018-06-30
PL2922844T3 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
ZA201503587B (en) N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
LT2712358T (en) Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
HK1215431A1 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
HK1217485A1 (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors raf / raf
HK1208678A1 (en) 3,5-diaminopyrazole kinase inhibitors 35-
EP2866893A4 (en) Heterocyclic guanidine f1f0-atpase inhibitors
EP2802324A4 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
HK1203848A1 (en) Tryptoline derivatives having kinase inhibitory activity and uses thereof tryptoline
IL237432B (en) Amine salt, crystals thereof and pharmaceutical composition comprising the same
TH1501002577A (en) Compounds N-pyrrolidinyl, N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine. It is used as a TRKA kinase inhibitor.
CL2014001265A1 (en) Compounds derived from uracil, axl and c-met kinase inhibitors, useful in the treatment of cancer.